NuCana Compliant with All Nasdaq Continued Listing Criteria

Rhea-AI Summary

NuCana (NASDAQ:NCNA) has announced its full compliance with all Nasdaq continued listing criteria, including the critical $1.00 minimum bid price requirement. The company has successfully resolved its previously disclosed Nasdaq listing concerns, with formal confirmation received on September 4, 2025.

Executive Chairman Andrew Kay highlighted that the company's current cash position, bolstered by ATM offering proceeds, is expected to fund operations into 2029. This extended runway will support multiple upcoming data readouts and key value-driving milestones in their cancer treatment development programs.

Positive

• Achieved full compliance with all Nasdaq listing requirements
• Cash runway extended into 2029 through successful ATM offering
• Multiple data readouts planned ahead

Negative

• Previous listing compliance issues required ATM offering, potentially diluting shareholders

News Market Reaction

+0.35%

1 alert

+0.35% News Effect

+$19K Valuation Impact

$5M Market Cap

0.4x Rel. Volume

On the day this news was published, NCNA gained 0.35%, reflecting a mild positive market reaction. This price movement added approximately $19K to the company's valuation, bringing the market cap to $5M at that time.

Data tracked by StockTitan Argus on the day of publication.

Anticipated Cash Runway into 2029

EDINBURGH, United Kingdom, Sept. 05, 2025 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) (“NuCana” or the “Company”) announced that it has received formal notification from The Nasdaq Stock Market on September 4, 2025 confirming that the Company is in compliance with all applicable Nasdaq continued listing criteria, including the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). As such, the previously disclosed Nasdaq listing matter has been closed.

“As a result of the decisive steps we have taken, NuCana is now fully compliant with Nasdaq’s continued listing standards,” said Andrew Kay, NuCana’s Executive Chairman. “We anticipate our existing cash resources, which include proceeds raised to date via an ATM offering, will be sufficient to fund our planned operations into 2029 and through a number of key value-driving milestones.”

“We appreciate the opportunity provided by the Nasdaq Hearings Panel to demonstrate our full compliance,” added Mr. Kay. “We now have a strong cash position and with multiple data readouts ahead, we are well-positioned to deliver on our mission of improving treatment outcomes for patients with cancer.”

About NuCana

NuCana is a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid and hematological tumors, they have significant shortcomings that limit their efficacy, and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome the key limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. NuCana’s pipeline includes NUC-7738 and NUC-3373. NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase 2 part of a Phase 1/2 study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a new chemical entity derived from the nucleoside analog 5-fluorouracil, a widely used chemotherapy agent. NUC-3373 is currently being evaluated in a Phase 1b/2 modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

Forward-Looking Statements
This press release may contain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of the Company. All statements other than statements of historical fact contained in this press release are forward-looking statements, including statements concerning the Company’s planned and ongoing clinical studies for the Company’s product candidates and the potential advantages of those product candidates, including NUC-7738 and NUC-3373; the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; the Company’s goals with respect to the development, regulatory pathway and potential use, if approved, of each of its product candidates; the utility of prior non-clinical and clinical data in determining future clinical results; and the sufficiency of the Company’s current cash and cash equivalents to fund its planned operations into 2029. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, our ability to raise additional capital sufficient to fund our planned operations and the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and subsequent reports that the Company files with the SEC. Forward-looking statements represent the Company’s beliefs and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, the Company assumes no obligation to publicly update any forward-looking statements for any reason after the date of this press release to conform any of the forward-looking statements to actual results or to changes in its expectations.

For more information, please contact:

NuCana plc
Andrew Kay
Executive Chairman
+44 131-357-1111
info@nucana.com

ICR Healthcare
Chris Brinzey
+1 339-970-2843
Chris.Brinzey@ICRHealthcare.com

FAQ

Has NuCana (NCNA) regained Nasdaq compliance in 2025?

Yes, NuCana received formal confirmation from Nasdaq on September 4, 2025, that it is now fully compliant with all continued listing criteria, including the $1.00 minimum bid price requirement.

How long will NuCana's current cash runway last?

NuCana's existing cash resources, including proceeds from their ATM offering, are expected to fund planned operations into 2029.

What are the next major milestones for NuCana (NCNA)?

The company has indicated multiple data readouts ahead and key value-driving milestones in their cancer treatment development programs, supported by their extended cash runway into 2029.

What steps did NuCana take to maintain Nasdaq listing?

NuCana implemented decisive measures including an ATM offering to strengthen its cash position and meet Nasdaq's continued listing requirements, particularly the $1.00 minimum bid price requirement.